Individuals with mutations in breast cancer susceptibility genes BRCA1 and BRCA2 have up to an 80% risk of developing breast cancer by the age of 70. Sequencing-based genetic tests are now available to identify mutation carriers in an effort to reduce mortality through prevention and early diagnosis. However, lack of a suitable functional assay hinders the risk assessment of more than 1,900 BRCA1 and BRCA2 variants in the Breast Cancer Information Core database that do not clearly disrupt the gene product. We have established a simple, versatile and reliable assay to test for the functional significance of mutations in BRCA2 using mouse embryonic stem cells (ES cells) and bacterial artificial chromosomes and have used it to classify 17 sequence variants. The assay is based on the ability of human BRCA2 to complement the loss of endogenous Brca2 in mouse ES cells. This technique may also serve as a paradigm for functional analysis of mutations found in other genes linked to human diseases.
Individuals with mutations in breast cancer susceptibility genes BRCA1 and BRCA2 have up to an 80% risk of developing breast cancer by the age of 70. Sequencing-based genetic tests are now available to identify mutation carriers in an effort to reduce mortality through prevention and early diagnosis. However, lack of a suitable functional assay hinders the risk assessment of more than 1,900 BRCA1 and BRCA2 variants in the Breast Cancer Information Core database that do not clearly disrupt the gene product. We have established a simple, versatile and reliable assay to test for the functional significance of mutations in BRCA2 using mouse embryonic stem cells (ES cells) and bacterial artificial chromosomes and have used it to classify 17 sequence variants. The assay is based on the ability of human BRCA2 to complement the loss of endogenous Brca2 in mouse ES cells. This technique may also serve as a paradigm for functional analysis of mutations found in other genes linked to human diseases.
Segregation analysis in cancer-afflicted families provides the most reliable information to distinguish between deleterious and neutral alterations identified in BRCA1 or BRCA2 (ref. 1). However, there is an enormous need for a functional assay to classify variants for which such information is not available, because most mutations are rare, and familial data are often insufficient. A few functional assays have been designed that either utilize transcriptional regulation activity or rely on functional complementation tests using BRCA1-deficient human tumor cells or BRCA2-deficient hamster cell lines 2 . Although these tests can distinguish between neutral and deleterious variants, such complementation assays have limited application because they rely on cDNA expression vectors to deliver mutant proteins to cells that are inherently prone to genomic instability.
RESULTS

Design of an ES cell-based functional assay
We have used mouse ES cells and bacterial artificial chromosomes (BACs) to design a functional assay to classify BRCA2 variants on the basis of the observation that BRCA2 is essential for ES cell viability 3 . We used the ability of human BRCA2 to rescue the lethality of Brca2-deficient ES cells to evaluate the functional significance of BRCA2 variants (Fig. 1a) and considered sequence variants that fail to rescue Brca2-deficient ES cells to be deleterious. In addition, we screened the nonlethal variants for a defect in the known function of BRCA2 in DNA repair to distinguish between a neutral variant and a deleterious variant that does not affect viability.
We generated a conditional allele of Brca2 by flanking the entire gene locus with two loxP sites along with two halves of the human hypoxanthine phosphoribosyl transferase (HPRT1) minigene in AB2.2 ES cells. These cells lack a functional Hprt gene and are sensitive to hypoxanthine, aminopterine and thymidine (HAT) selection (HAT s ) 4 . In the presence of Cre, the two loxP sites will recombine and generate a functional HPRT1 minigene, allowing the recombinant clones to grow in HAT medium. (Supplementary Figs. 1 and 2 online) . We then disrupted the second copy of Brca2 by introducing a blasticidin resistance gene into exon 11 of the gene ( Supplementary Fig. 3 online). When we transiently expressed Cre in one of the resulting ES cell clones (Pl2F7), we obtained only five to ten HAT r colonies (background colonies that retained a wild-type copy after we plated 1 Â 10 5 cells). Control cells carrying a conditional and a wild-type allele of Brca2 yielded 4,000-6,000 colonies (data not shown).
Next, we rescued the lethality of Brca2-deficient ES cells by electroporating a human BRCA2-containing BAC retrofitted with a neomycin resistance gene (neo) into Pl2F7 cells. We tested three independent neo r clones showing the presence of the 5¢ and 3¢ portions of BRCA2 (Fig. 1b) and expressing different levels of human BRCA2 protein (Fig. 1c) . All three clones yielded thousands of HAT r colonies that lacked endogenous Brca2 (Fig. 1d,e) .
Distinguishing between deleterious and neutral variants
To assess the ability of this system to distinguish between a deleterious and a neutral variant, we generated four mutations (279delAC, 6174delT, N991D and D2723H) with well-established functional effects [5] [6] [7] in the BAC. First, we examined two known deleterious mutations: the 279delAC deletion that results in a stop signal at codon 29 (stop29) and the 6174delT mutation that truncates the protein at codon 2003 (ref. 5 ; Fig. 1f ). As expected, these mutations could not rescue the ES cell lethality, supporting their deleterious phenotype (Fig. 1f) .
To further assess the validity of our assay, we tested two missense variants, N991D, a known polymorphism 6 , and D2723H, a known deleterious missense mutation 7 . ES cells expressing the N991D variant survived after the deletion of the endogenous Brca2 and showed no difference in sensitivity to various DNA-damaging agents when compared to control cells (Supplementary Table 1 online). We found the D2723H mutant protein exclusively in the cytoplasmic fraction (Fig. 2a) , as reported previously 7 . In our assay, it did not rescue the ES cells after Cre expression (data not shown). Our results confirm that D2723H is a deleterious and N991D is a neutral BRCA2 variant, demonstrating our assay's ability to successfully distinguish between deleterious and neutral alterations.
Functional evaluation of additional variants
We then selected a panel of sequence variants ( Table 1) to further validate the system and to show its applicability for testing variants with different degrees of evolutionary conservation, with alterations found in different functional domains and with conflicting or unclear functional data, as well as one splicing variant. In addition, we have generated a hypomorphic allele and examined its phenotype in detail with various functional assays.
We first tested seven BRCA2 variants ( Table 1) , five of them (Y42C, D1420Y, V2728I, E2856A and S2988G) with limited evolutionary conservation and two (E2663V, G2901D) conserved across the animal kingdom and plants. All less conserved variants sustained the ES cell viability after the endogenous Brca2 was deleted and did not show hypersensitivity to any DNA-damaging agents (data not shown). Four of these mutations, with the exception of S2988G that was found only once, have been frequently recorded in the Breast Cancer Information Core database 8 , and epidemiological data ( Table 1 ) strongly suggested that these were neutral variants. Despite these data, Y42C was shown by in vitro studies to disrupt an interaction between the amino terminus of BRCA2 and the replication protein A (ref. 9), a protein essential for DNA repair, which directly contradicts the epidemiological studies 10 . The lack of any deleterious effect of Y42C in ES cells further validates our experimental system and reveals limitations of experiments in which an isolated portion of the protein is used to draw conclusions about causality.
The pathogenic potential of two evolutionary conserved variants, G2901D and E2663V, was unknown (see Table 1 ). Our assay shows that G2901D has no effect on BRCA2 function (Supplementary Table 1 online), suggesting that this mutation is neutral. The other variant, E2663V, did not rescue the cells after the Cre expression and, thus, should be classified as deleterious. Interestingly, it has recently been reported as a variant with high probability to be classified as deleterious 11 .
Assays to evaluate BRCA2 function
In an effort to show the usefulness of ES cells to perform various assays to examine BRCA2 function, we generated a known deleterious mutation that results in a protein truncated at codon 3308 (Y3308X) 8 . We expected this mutation to be a hypomorphic allele on the basis of the phenotype of mice that have a similar truncating mutation in Brca2 (exon 27 deletion) 12, 13 . Evaluation of the Y3308X variant in our assay was also relevant to a similar truncation involving the next codon, E3309X, found in a woman with ovarian cancer (W. Foulkes, McGill University, personal communication). Given the deleterious nature of the Y3308X variant, we expected E3309X to be deleterious as well. However, the fact that another BRCA2 variant that truncates the protein just a few amino acids downstream (K3326X) is neutral added ambiguity to our interpretation 14 . We therefore tested these three truncations in our assay. We obtained viable ES cell clones expressing an Y3308X transgene, as confirmed by RT-PCR (Fig. 1f) , but observed a 80-90% reduction in the number of HAT r colonies (data not shown). The mutant cells grew considerably more slowly in vitro as well as in vivo ( Supplementary Fig. 4a ,b online). These cells had a reduced plating efficiency and were hypersensitive to crosslinking and methylating agents, as well as ionizing radiation (Supplementary Table 1 and Supplementary Fig. 5 online) , which is consistent with drug sensitivities known for Brca2-deficient cell lines [15] [16] [17] [18] . Because of the known role of BRCA2 in homologous recombination 15 , we tested the efficiency of homologous recombination in Y3308X-mutant ES cells using two gene-targeting vectors. One was designed to target a genomic locus located 150 kilobases (kb) upstream of Brca1 ( Supplementary Fig. 6a ,b online) and contained a negative selection marker, the gene encoding diphtheria toxin gene. The second construct, which targeted the Gt(ROSA)26Sor locus (abbreviated here as Rosa26), lacked a negative selection marker (Supplementary Fig. 6c,d) . Although the control cells showed a targeting efficiency within the range of normal experimental variation, we did not observe a single correctly targeted clone in cells expressing Y3308X BRCA2 (Fig. 2b) , suggesting a defect in the homologous recombination process.
BRCA2 has a key role in the recruitment of RAD51 to the sites of DNA repair 19 ; therefore, we examined the effect of the Y3308X mutation on radiation-induced RAD51 foci formation. We observed, on average, 32 RAD51 foci per cell after irradiation (10 Gy) in control cells, whereas we found zero or occasionally only one or two RAD51 foci in the mutant cells (Fig. 2c-e) . These results provide additional evidence of a defect in RAD51-mediated DNA repair in cells expressing the Y3308X variant.
One of the hallmarks of BRCA2-deficient cells is a marked increase in genomic instability, predisposing them to tumorigenesis 20 . Karyotyping revealed, on average, 68 chromosomal aberrations such as chromatid gaps and breaks, radial structures and fragmented chromosomes per 100 mutant cells versus 10.5 aberrations per 100 control cells (Fig. 2f-h ). The extent of genomic instability in Y3308X mutant cells strongly suggests that this variant is likely to predispose a cell to tumorigenesis. Notably, we found elevated amounts of p53 and p21 proteins in nonirradiated mutant cells (Supplementary Fig. 4c ).
This elevated DNA damage response may explain the defects in cell proliferation and plating efficiency of the Y3308X mutant cells.
We also tested the K3326X truncation in our assay and found no effect on BRCA2 function (Supplementary Table 1 and Supplementary Fig. 5 ), which corroborates this truncation's classification as a neutral variant. In contrast, E3309X mutant ES cells had reduced viability and were hypersensitive to various DNA-damaging agents (Supplementary Table 1 and Supplementary Fig. 5 ). We therefore concluded that, like Y3308X, E3309X is a deleterious variant.
Examining aberrant splicing
We have previously demonstrated the reliability of using human BACs in mouse ES cells to study BRCA1 splicing mutations 21 . Here, we tested a BRCA2 missense variant T2722R that was recently reported to cause aberrant splicing and results in deletion of exon 18 in the transcript 22 . Indeed, in mutant ES cells we found transcripts lacking exon 18 (D18, Fig. 3a,b) . However, by using RT-PCR and western blot analysis, we found that the major product of this allele is the full-length protein (Fig. 3a,c) . We believe that, unlike in ES cells used in our studies, in tissue samples from individuals who are heterozygous, such products may have escaped detection owing to the presence of wild-type BRCA2. Nevertheless, the full-length T2722R BRCA2 did not rescue ES cell viability, corroborating our conclusion that the mutation is deleterious.
Comparing the effects of R3052Q and R3052W variants Finally, we tested the impact of different amino acid substitutions at a single position. We examined the arginine at position 3052, located at the interface between oligonucleotide-oligosaccharide-binding folds 2 and 3 (OB2 and OB3, respectively) of the human BRCA2 protein 23 , which is found to be changed to either glutamine (R3052Q) or tryptophan (R3052W) in the human population ( Table 1) . A recent study shows R3052Q to have relatively low score in favor of neutrality 11 . Arginine at this position makes hydrogen bonds with four neighboring amino acid residues, two from each of the OB folds, thus linking them together (Fig. 3d) . On the basis of a computer simulation, we predicted the R3052Q variant to have an activity either similar or partially reduced compared to the wild-type BRCA2, whereas we expected the R3052W alteration to severely disrupt the protein function (Fig. 3d) . In our assay, ES cells expressing the R3052W variant did not survive (Fig. 3e) , suggesting it to be deleterious. In contrast, we obtained viable R3052Q-expressing ES cells, and there was no difference in the number of colonies compared to control cells (Fig. 3e) . When challenged with DNA-damaging drugs, R3052Q ES cells showed no sensitivity to g-irradiation and ultraviolet (UV) light but a moderate sensitivity to mitomycin C, methyl methane-sulfonate, N-methyl-N¢-nitro-N-nitrosoguanidine and cisplatin ( Fig. 3f and Supplementary Table 1) , which suggests only a partial loss of BRCA2 function. The moderate defect in BRCA2 function associated with the R3052Q variant may potentially contribute to developing cancer, albeit at a low risk. Future studies may provide unequivocal proof for the pathogenicity of R3052Q variant. An alternative approach to evaluate the role of such variants in tumorigenesis is to study them in mouse models. We have introduced the D2723H variant into mice and found it to result in embryonic lethality, which proves the deleterious nature of this variant (S.G.K. and S.K.S., unpublished data). Such deleterious mutations can be studied with a conditional knockout allele of Brca2 to evaluate their roles in tumor development.
DISCUSSION
We have provided here a preliminary validation of our ES cell-based functional assay for evaluating mutations in human BRCA2 by testing 17 variants. Although the ultimate validation of this assay in a true epidemiological sense is not possible at present, for 13 variants (four truncating variants, excluding E3309X, plus eight missense variants, Y42C, N991D, D1420Y, E2663V, D2723H, V2728H, E2856A and R3052Q, and one missense mutation, T2722R, which also affects splicing), the results obtained in our assay completely agreed with predictions based on epidemiological studies and other available functional data 6, 7, 13, 24 . The functional importance of four other mutations (E3309X, G2901D, S2988G and R3052W) was unknown and was reported here for the first time, to our knowledge. Future studies will show how the range of phenotypes revealed for different mutations, that is, cell lethality, degree of sensitivity to DNA-damaging agents and, possibly, specific sensitivity to only a subset of toxic compounds, correlates with their penetrance and disease presentation in humans.
We have established that this assay is accurate and is one of the most comprehensive among those available to date, allowing analysis of virtually any type of mutation, and it may also serve as a model for investigating other human disease-associated genes that result in a phenotype detectable in ES cells. We have streamlined the process of mutation analysis. Three to five of such sequence variants can be analyzed within 2-3 months (time for each procedure is specified in Fig. 4 ). This makes our assay a useful, tractable and viable tool for genetic counselors. However, until the assay is fully validated, caution must be exercised when using these data to make clinical decisions.
METHODS
Generation of mutations in BRCA2 in a bacterial artificial chromosome clone. We used BAC RP11-777I19, containing the full-length human BRCA2 gene 25 , to generate mutations. We introduced the mini-lambda-based 'recombineering' (recombination-mediated genetic engineering) system into BACcontaining DH10B cells as described previously 26 . The loxP site was deleted and loxP511 was replaced with a neomycin resistance gene under the control of the Pgk promoter to enable a positive selection of transgenic ES cells. We introduced mutations with the oligonucleotide-based 'hit and fix' BAC recombineering method as described previously 27 . We confirmed all mutations by sequencing.
Generation of Brca2-null ES cells carrying a mutant transgene. We cultured mouse embryonic stem cells in M15 media (Knockout DMEM (Gibco)) and supplemented it with 15% FBS (HyClone), glutamate-penicillin-streptomycin (Gibco) and 0.1 mM b-mercaptoethanol with SNL (feeder cells expressing leukemia inhibitory factor and the neomycin resistance gene) feeder cells. We electroporated 25 mg BAC DNA into 1 Â 10 7 Pl2F7 ES cells (for details on the Figure 4 Evaluation of BRCA2 variants. Schematic representation of the assay designed to examine functional significance of mutations in the human BRCA2 gene in mouse ES cells as described in the text. The time required for each individual procedure is indicated in parentheses below step description.
generation of these cells from the AB2.2 cell line, see Supplementary Figs. 1-3 (Fig. 1b) .
We further tested double-positive clones for expression of BRCA2 by RT-PCR and western blot analysis. We electroporated BRCA2-expressing clones with Pgk-Cre plasmid 4 and seeded 1 Â 10 5 cells in a 100-mm dish with SNL feeder cells. We selected recombinant colonies in the HAT media (Gibco) for 5 d, followed by 2 d in HT media (Gibco). We analyzed viable colonies by Southern blotting to confirm the loss of the conditional Brca2 allele. We used a 1.5-kb probe specific to Brca2 exon 11 (nucleotides 5208-6710 of NM_009765) to detect a 2.2-kb EcoRV fragment corresponding to the mutant allele (ko) and a 4.8-kb fragment corresponding to the wild-type or conditional allele (cko) (Fig. 1e and Supplementary Fig. 3 ). We also stained HAT r colonies with methylene blue (2% methylene blue (wt/vol) in 70% ethanol for 15 min followed by washing with 70% ethanol) to facilitate their quantification.
Expression analysis. For western blot analysis, we extracted proteins in RIPA buffer (50 mM Tris-HCl, pH 7.4, 1 mM EDTA, 150 mM NaCl, 0.1% SDS, 1% Triton X-100, 0.25% sodium deoxycholate, 1 mM sodium fluoride, 1 mM orthovanadate). We used the NE-PER buffer system (Pierce) to isolate nuclear and cytoplasmic protein fractions. We then separated proteins on a precast NuPAGE 4-12% Bis-Tris gel (Invitrogen) in MOPS SDS running buffer (Invitrogen). We used antibodies to the following proteins: BRCA2 (Ab-2, Calbiochem, 1:500), actin (Ab-5, NeoMarkers, 1:1,000), p53 (CM5p, Novocastra), p21 (F-5, Santa Cruz). Secondary antibodies were horseradish peroxidase (HRP)-conjugated goat antibody to rabbit IgG (sc-2004, Santa Cruz) at a 1:5,000 dilution and HRP-conjugated goat antibody to mouse IgG (sc-2005, Santa Cruz) at a 1:2,000 dilution. We used ECL Plus Western Blotting Detection system (Amersham) for chemiluminescent detection.
As an alternative to western blotting, we tested BRCA2 transgene expression by standard RT-PCR techniques using a forward primer 5¢-ACATGTCCC GAAAATGAGGA-3¢ and a reverse primer 5¢-GCCGATCTTCTGCTTCTAT CA-3¢ residing in exons 11 and 18, respectively, and amplifying a 1,250-bp fragment (Fig. 1f) . To detect alternatively spliced products in ES cells expressing T2722R mutant BRCA2, we synthesized cDNA with a sequence-specific primer 5¢-CCTCCTGAATTTTAGTGAATAAGGCTTCTAGTCTC-3¢. PCR amplification was carried out with forward primer 5¢-AGGGCTCTGTGTGA CACTCC-3¢ and a reverse primer 5¢-GCAGGCCGAGTACTGTTAGC-3¢ residing in exons 17 and 19, respectively, using standard PCR conditions. The 554-bp fragment corresponded to a full-length product containing exon 18, and a 199-bp fragment corresponded to an alternatively spliced isoform lacking exon 18 (Fig. 3a,b) .
Genotoxin sensitivity assay. We seeded 8,000 ES cells per well (16,000 cells per well for Y3308X and E3309X mutants to compensate for lower seeding and growth efficiency) in 96-well plates in two to four replicas. We started drug treatment 18 h later (concentrations indicated in Supplementary Fig. 5 ). For UV sensitivity testing, we seeded 32,000 ES cells (64,000 cells for Y3308X and E3309X) per well in triplicates in 24-well plates. The next day, we irradiated cells (without media) at the indicated doses ( Supplementary Fig. 5g ) in a UV crosslinker (Stratagene) and then cultured in fresh media. For g-irradiation, we exposed plates to a 137 Cs source at 146.3 rad min -1 without media change. We measured the relative number of living cells 72 h later by XTT (2,3-bis (2-methoxy-4-nitro-5-sulfophenyl)-5-[(phenylamino)carbonyl]-2H-tetrazolium hydroxide) assay 28 . We adjusted values for 'no cells' background.
RAD51 foci formation assay. We plated 40,000 cells per well in gelatinized SonicSeal plastic slides (NUNC). We irradiated slides 48 h later with 10 Gy. Six hours later, we fixed cells with 4% paraformaldehyde for 5 min, washed them twice with PBS and permeabilized them in PBS-buffered 0.1% Triton X-100 for 10 min. After two additional washes with PBS, we blocked cells in a blocking solution (1% BSA, 0.05% Triton X-100, 10% donkey serum in PBS). We performed antibody staining and imaging as described previously 29 .
Homologous recombination assay. We electroporated exponentially growing ES cells with each of the targeting vectors described in Supplementary Figure 6 online. We selected clones for resistance to hygromycin or puromycin. We analyzed 96 colonies from each cell line for homologous recombination by Southern blot analysis as shown in Supplementary Figure 6 .
Karyotyping. We treated ES cells with colcemid (Invitrogen) for 1.5 h to arrest them at metaphase. We trypsinized, washed and resuspended the cells in hypotonic solution at 37 1C (0.075M KCl) for 15 min and fixed them in a methanol-acetic acid mixture (3:1 vol/vol). We stained air-dried preparations in Giemsa solution (10% Sorensen's buffer and 2% Giemsa, J.T. Baker). We blindly examined 200 well spread metaphases containing at least 40 chromosomes from each genotype for structural aberrations.
Crystal structure modeling. We retrieved the crystal structure for a C-terminal portion of mouse BRCA2 from the protein data bank at http://www.rcsb.org/ (accession code 1MIU) and analyzed it with Sirius software available at http:// sirius.sdsc.edu/ and DS ViewerPro from Accelrys Software.
Statistical analyses. We evaluated the results obtained from testing mutant ES cells for sensitivity to genotoxins for statistical significance by analysis of variance. Because Y3308X and E3309X cells showed an identical phenotype, we later tested them as one group (n ¼ 6) against the group of controls (two wild-type clones and the K3326X polymorphism, n ¼ 9) using a two-tailed t-test with unequal variance.
Note: Supplementary information is available on the Nature Medicine website.
